The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 5, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 5.
Number 5: According to a new review of the literature, managed care professionals can help providers to personalize treatment for patients with macular degeneration, and can encourage adherence.
Number 4: A recent cross-sectional study found that the uptake of biosimilars in the United Kingdom has been highly variable and generally lower than expected.
Number 3: Sales of MabThera dropped sharply due to competition from biosimilars in the European Union.
Number 2: YL Biologics has reported positive phase 3 clinical trial results for its proposed biosimilar referencing Erelzi.
Number 1: The American College of Rheumatology has released a new white paper that supports the use of biosimilars in clinical practice.
Also this week, Dr Robert Levin, a practicing rheumatologist and patient advocate, wrote in The Center for Biosimilars® that, if HHS wants to confront the problem of high drug prices, it must address the growing role of pharmacy benefit managers.
Finally, last week, our e-newsletter asked whether physicians’ expectations of clinical trials are hindering biosimilar acceptance.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.